ロード中...
Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers
Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In th...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
2004
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC400571/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15105105/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.5.1553-1560.2004 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|